-
Entrada shares updates on Duchenne programs, including initiation of Cohort 2 in UK and EU trial skipping exon 45
As an early funder of Entrada Therapeutics, we are pleased to share their latest newsletter
-
Adults with MD report major gaps in sexual, reproductive healthcare: Study
Adults with muscular dystrophy (MD) in the U.S. report widespread gaps in sexual and reproductive
-
Sarepta Webinar
ELEVIDYS Gene Therapy Update and ENDEAVOR Cohort 8 Awareness Watch HERE Recorded: May 19, 2024
-
Tevard Webinar
Unlocking the therapeutic power of suppressor tRNAs for DMD Watch HERE Recorded Thursday, May 28,
-
Regenxbio Webinar
RGX-202: Investigational Gene Therapy for Duchenne Muscular Dystrophy Pivotal Data Update from the AFFINITY DUCHENNE®
-
Servier’s Acquisition of Edgewise’s Sevasemten Marks Major Milestone for Becker and Duchenne Muscular Dystrophy Communities
The neuromuscular disease community received encouraging news this week as Edgewise Therapeutics announced the sale of
